Cancer BiologybioRxiv
Patients with mesenchymal tumours and high Fusobacteriales prevalence have worse prognosis in colorectal cancer (CRC)
DOI 10.1136/gutjnl-2021-325193
Author
N. T. Crawford
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
Biology Disciplines
Click to filter author papersSignature Assays, Organisms & Methods
Click to filter · or open tagOrganism:human· 3Approach:experimental assay· 2Assay:bulk RNA-seq· 1Research Focus:cancer & tumor microenvironment· 1Research Focus:cell signaling & trafficking· 1Research Focus:development & morphogenesis· 1Research Focus:drug response / drug discovery· 1Research Focus:host-pathogen & immune response· 1
Activity by Year
2019-2021 · peak 1/yrCo-Author Collaboration Network
10 top collaborators · 45 mutual co-author linksFocal author (center)Selected co-authorORCID co-authorUnlinked name
Curved chords = mutual co-authorship3 papers
Recent·Most cited
- Cancer BiologybioRxiv
Clinical positioning of the IAP antagonist tolinapant (ASTX660) in colorectal cancer
D. B. Longley, N. T. Crawford, K. J. Stott…·V. M. Coyle
This study shows tolinapant, an IAP inhibitor, enhances chemotherapy-induced apoptosis in colorectal cancer by modulating FLIP and HDACs, suggesting its clinical use in poor prognosis MSS CRC with elevated cIAP1/2.
DOI 10.1158/1535-7163.mct-20-1050